On November 12, the heart pulse medical care rose 5.05%, as of 10:07, reported at 11.296 yuan/share, with a turnover of 246 million yuan, a renewal rate of 1.81%, and a total market value of 13.924 billion yuan.
According to the data, Shanghai Minimally Invasive Heart Period Medical Technology (Group) Co., Ltd. is located at No. 3399, Kangxin Highway, Pudong New District, Shanghai.Companies of the development, production, sales and services of peripheral vascular intervention in medical devices have 13 listed products, and the products have entered over 1,900 hospitals across the country, saving the lives of more than 220,000 patients.The companys domestic market share in the companys active artery cavity reaches 29%, ranking first in the Chinese market. The international business covers 28 countries and regions in Europe, Latin America, Southeast Asia and other places.The above increased year by year, R & D personnel accounted for nearly 30%of the companys total employees, and more than 280 domestic and overseas authorized patents were obtained.
As of September 30, the number of households in the heart pulse medical shareholders was 16,100, and the per capita circulation shares were 7,634 shares.
From January-September 2024, the operating income of heart pulse medical treatment was 970 million yuan, an increase of 9.13%year-on-year; the net profit attributable to 553 million yuan, a year-on-year increase of 42.46%.
This article comes from: the financial industry
Author: A-share Jun
